$MBIO
MUSTANG BIO, INC. Stock $mbio

$mbio Overview Financials Valuation SEC Filings Company Website

2017 Form 10-K Financial Statement

#000114420418017988 Filed on March 29, 2018

Income Statement

Concept	2017	2016 Q4	2016 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.41M	$1.000M	$1.100M
YoY Change	304.61%	1150.0%	1122.22%
% of Gross Profit
Research & Development	$100.0K	$6.830M	$500.0K
YoY Change	-95.0%	798.68%	0.0%
% of Gross Profit
Depreciation & Amortization	$2.000K
YoY Change
% of Gross Profit
Operating Expenses	$31.79M	$7.830M	$1.670M
YoY Change	179.72%	832.14%	153.8%
Operating Profit	-$31.79M	-$7.831M	-$1.670M
YoY Change	179.72%	828.94%	153.8%
Interest Expense	$500.0K	-$920.0K	-$200.0K
YoY Change	-138.76%	1214.29%	233.33%
% of Operating Profit
Other Income/Expense, Net	$497.0K	-$917.0K	-$200.0K
YoY Change	-138.5%	1248.53%	244.83%
Pretax Income	-$31.29M	-$8.750M	-$1.870M
YoY Change	147.35%	861.54%	159.72%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$31.29M	-$8.748M	-$1.870M
YoY Change	147.26%	860.26%	161.17%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.239M	-$346.9K	-$74.15K
COMMON SHARES
Basic Shares Outstanding		13.08M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017	2016 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$61.00M	$27.50M	$11.10M
YoY Change	121.82%
Cash & Equivalents	$35.00M	$27.50M	$11.12M
Short-Term Investments	$26.00M
Other Short-Term Assets	$300.0K
YoY Change
Inventory
Prepaid Expenses		$0.00
Receivables
Other Receivables
Total Short-Term Assets	$61.40M	$27.50M	$11.12M
YoY Change	123.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.400M	$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$800.0K	$0.00
YoY Change
Total Long-Term Assets	$2.100M	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$61.40M	$27.50M	$11.12M
Total Long-Term Assets	$2.100M	$0.00	$0.00
Total Assets	$63.50M	$27.50M	$11.12M
YoY Change	130.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.600M	$700.0K	$1.000M
YoY Change	414.29%
Accrued Expenses	$0.00	$500.0K	$1.200M
YoY Change	-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$300.0K	$2.000M
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.600M	$3.223M	$4.869M
YoY Change	12.5%	-21.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$2.900M
YoY Change
Other Long-Term Liabilities	$100.0K
YoY Change
Total Long-Term Liabilities	$100.0K	$0.00	$2.900M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.600M	$3.223M	$4.869M
Total Long-Term Liabilities	$100.0K	$0.00	$2.900M
Total Liabilities	$3.700M	$3.223M	$7.800M
YoY Change	15.63%	-21.94%
SHAREHOLDERS EQUITY
Retained Earnings		-$17.12M	-$8.372M
YoY Change		283.34%
Common Stock		$37.00M	$11.69M
YoY Change		25242.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$59.80M	$24.28M	$3.322M
YoY Change
Total Liabilities & Shareholders Equity	$63.50M	$27.50M	$11.12M
YoY Change	130.91%

Cashflow Statement

Concept	2017	2016 Q4	2016 Q3
OPERATING ACTIVITIES
Net Income	-$31.29M	-$8.748M	-$1.870M
YoY Change	147.26%	860.26%	161.17%
Depreciation, Depletion And Amortization	$2.000K
YoY Change
Cash From Operating Activities	-$12.95M	-$2.260M	-$570.0K
YoY Change	213.59%	326.42%	-45.19%
INVESTING ACTIVITIES
Capital Expenditures	$424.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$28.63M	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$29.05M	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	49.98M	18.65M	11.68M
YoY Change	58.01%	3418.87%	284.21%
NET CHANGE
Cash From Operating Activities	-12.95M	-2.260M	-570.0K
Cash From Investing Activities	-29.05M	0.000	0.000
Cash From Financing Activities	49.98M	18.65M	11.68M
Net Change In Cash	7.976M	16.39M	11.11M
YoY Change	-71.0%	-7039451398144001000.0%
FREE CASH FLOW
Cash From Operating Activities	-$12.95M	-$2.260M	-$570.0K
Capital Expenditures	$424.0K
Free Cash Flow	-$13.37M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	59832000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	27499000	USD
CY2016Q4	us-gaap	Assets Assets	27499000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	683000	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2017Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	9558000	USD
CY2016Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	4396000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	98679000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	36998000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48408000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17120000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	24276000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63493000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27499000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	278000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	USD
CY2017Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	26002000	USD
CY2016Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	0	USD
CY2017Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	34975000	USD
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	27499000	USD
CY2017Q4	ck0001680048	Common Shares Issuable Liability Current CommonSharesIssuableLiabilityCurrent	0	USD
CY2016Q4	ck0001680048	Common Shares Issuable Liability Current CommonSharesIssuableLiabilityCurrent	1682000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	61361000	USD
CY2017Q4	us-gaap	Assets Assets	63493000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3474000	USD
CY2017Q4	ck0001680048	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	0	USD
CY2016Q4	ck0001680048	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	413000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.24
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	ck0001680048	Payables And Accruedexpenses Related Parties Current PayablesAndAccruedexpensesRelatedPartiesCurrent	137000	USD
CY2016Q4	ck0001680048	Payables And Accruedexpenses Related Parties Current PayablesAndAccruedexpensesRelatedPartiesCurrent	445000	USD
CY2017	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7943000	USD
CY2017	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	12433000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11409000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-31785000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	497000	USD
CY2016	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	6079000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2816000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	31785000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	11363000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-11363000	USD
CY2017	us-gaap	Interest Income Other InterestIncomeOther	505000	USD
CY2016	us-gaap	Interest Income Other InterestIncomeOther	16000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-12654000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.15
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11026666	shares
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-31288000	USD
CY2017	ck0001680048	Interest Income Expenses Related Party InterestIncomeExpensesRelatedParty	0	USD
CY2016	ck0001680048	Interest Income Expenses Related Party InterestIncomeExpensesRelatedParty	-253000	USD
CY2017	us-gaap	Interest Expense Debt InterestExpenseDebt	8000	USD
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	895000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	159000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1332000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	668000	USD
CY2017	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	12000	USD
CY2016	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-250000	USD
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-413000	USD
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	245000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2375000	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2017	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	320000	USD
CY2016	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2001000	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	4396000	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	190000	USD
CY2017	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2875000	USD
CY2016	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2017	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	1234000	USD
CY2016	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	862000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	278000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	0	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	2012000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2017	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	46002000	USD
CY2016	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	763000	USD
CY2017	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	106000	USD
CY2016	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	USD
CY2017	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	424000	USD
CY2016	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	0	USD
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25252832	shares
CY2016	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2468000	USD
CY2017	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	817000	USD
CY2016	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	0	USD
CY2017	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2016	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	793000	USD
CY2017	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2016	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	2221000	USD
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2062000	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2016Q2	ck0001680048	Founders Agreement Term FoundersAgreementTerm	P15Y
CY2017	us-gaap	Officers Compensation OfficersCompensation	25052	USD
CY2017Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	200000	USD
CY2017Q4	ck0001680048	Number Of Shares To Be Issued Upon Legal Settlement NumberOfSharesToBeIssuedUponLegalSettlement	200000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017	ck0001680048	Class Of Warrant Or Right Percentage Of Warrant Issued ClassOfWarrantOrRightPercentageOfWarrantIssued	0.25	pure
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	5.73
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5.73	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2017Q1	ck0001680048	Warrants Issued WarrantsIssued	16000	shares
CY2017Q1	ck0001680048	Warrants Issued WarrantsIssued	2134193	shares
CY2017Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	106000	USD
CY2016Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	0	USD
CY2017Q4	ck0001680048	Property Plant And Equipment Excluding Assets Under Construction PropertyPlantAndEquipmentExcludingAssetsUnderConstruction	140000	USD
CY2016Q4	ck0001680048	Property Plant And Equipment Excluding Assets Under Construction PropertyPlantAndEquipmentExcludingAssetsUnderConstruction	0	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	251000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2017Q4	ck0001680048	Construction In Process Net ConstructionInProcessNet	1241000	USD
CY2016Q4	ck0001680048	Construction In Process Net ConstructionInProcessNet	0	USD
CY2017Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	50000	USD
CY2016Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	0	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3611000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3223000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	3661000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	3223000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25236255	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25236255	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15165244	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15165244	shares
CY2017Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	834756	shares
CY2016Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	767264	shares
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1707000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2337000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	254000	USD
	us-gaap	Operating Expenses OperatingExpenses	4298000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4298000	USD
	us-gaap	Interest Income Other InterestIncomeOther	0	USD
	ck0001680048	Interest Income Expenses Related Party InterestIncomeExpensesRelatedParty	-168000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-168000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4466000	USD
CY2017	ck0001680048	Potentially Dilutive Securities PotentiallyDilutiveSecurities	7058993	shares
CY2016	ck0001680048	Potentially Dilutive Securities PotentiallyDilutiveSecurities	2493664	shares
	ck0001680048	Potentially Dilutive Securities PotentiallyDilutiveSecurities	0	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9993197	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.45
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000	USD
CY2016Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35475000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27499000	USD
CY2016	ck0001680048	Stock Issued During Period Value Issued For Founders Agreement StockIssuedDuringPeriodValueIssuedForFoundersAgreement	862000	USD
CY2016	ck0001680048	Stock Issuance Common Stock Issuable During Period StockIssuanceCommonStockIssuableDuringPeriod	4396000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	39098000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4090000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	793000	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2017	ck0001680048	Stock Issuance Common Stock Issuable During Period StockIssuanceCommonStockIssuableDuringPeriod	9558000	USD
CY2017	ck0001680048	Stock Issued During Period Value Issued For Founders Agreement StockIssuedDuringPeriodValueIssuedForFoundersAgreement	1234000	USD
CY2017	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	1682000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55970000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5674000	USD
CY2017	ck0001680048	Adjustment To Additional Paid In Capital Capital Contribution AdjustmentToAdditionalPaidInCapitalCapitalContribution	2062000	USD
CY2017	ck0001680048	Share Issued During Period Valueon Exercise Of Warrants ShareIssuedDuringPeriodValueonExerciseOfWarrants	0	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2000000	USD
	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	0	USD
CY2017	ck0001680048	Common Stock Issuable For Founder Agreement CommonStockIssuableForFounderAgreement	9558000	USD
CY2016	ck0001680048	Common Stock Issuable For Founder Agreement CommonStockIssuableForFounderAgreement	4396000	USD
	ck0001680048	Common Stock Issuable For Founder Agreement CommonStockIssuableForFounderAgreement	190000	USD
CY2017	ck0001680048	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	0	USD
CY2016	ck0001680048	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	1682000	USD
	ck0001680048	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	147000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2017	us-gaap	Depreciation Depreciation	2000	USD
CY2016	us-gaap	Depreciation Depreciation	0	USD
	us-gaap	Depreciation Depreciation	0	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	0	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	15000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	375000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	168000	USD
CY2017	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-50000	USD
CY2016	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	20000000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000000	USD
	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	3571000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	ck0001680048	Proceeds From Notes Payable Gross ProceedsFromNotesPayableGross	0	USD
CY2017	ck0001680048	Proceeds From Notes Payable Gross ProceedsFromNotesPayableGross	0	USD
CY2016	ck0001680048	Proceeds From Notes Payable Gross ProceedsFromNotesPayableGross	-3600000	USD
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50296000	USD
CY2016	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	35008000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7976000	USD
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27499000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	0	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2015Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	0	USD
CY2017	ck0001680048	Property Plant And Equipment Included In Accounts Payable And Accrued Liabilities PropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	142000	USD
CY2016	ck0001680048	Property Plant And Equipment Included In Accounts Payable And Accrued Liabilities PropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	0	USD
	ck0001680048	Property Plant And Equipment Included In Accounts Payable And Accrued Liabilities PropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	0	USD
	us-gaap	Stock Issued1 StockIssued1	1000	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2017	ck0001680048	Class Preferred Stock Exchanged For Common Stock ClassPreferredStockExchangedForCommonStock	0	USD
CY2016	ck0001680048	Class Preferred Stock Exchanged For Common Stock ClassPreferredStockExchangedForCommonStock	1000	USD
	ck0001680048	Class Preferred Stock Exchanged For Common Stock ClassPreferredStockExchangedForCommonStock	0	USD
CY2017	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2016	us-gaap	Notes Assumed1 NotesAssumed1	3471000	USD
	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2017	ck0001680048	Stock Issuable For License Acquired StockIssuableForLicenseAcquired	1682000	USD
CY2016	ck0001680048	Stock Issuable For License Acquired StockIssuableForLicenseAcquired	0	USD
	ck0001680048	Stock Issuable For License Acquired StockIssuableForLicenseAcquired	0	USD
CY2016Q2	ck0001680048	Additional Consideration Under Founders Agreement Description AdditionalConsiderationUnderFoundersAgreementDescription	(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Company’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of the Company’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%) (see Note 8).
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5674000	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4090000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-7831000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3306000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5665000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7084000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-15730000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	144000	USD
CY2017Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	129000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-81000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-93000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-200000	USD
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-917000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-6940000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-15601000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-903000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-1133000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-1870000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-8748000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.13	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.09	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.02	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.03	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.01	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.01	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.22	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.47	pure
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2017	ck0001680048	Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Ratepercent EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatepercent	-0.18	pure
CY2016	ck0001680048	Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Ratepercent EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatepercent	0	pure
CY2017	ck0001680048	Effective Income Tax Rate Reconciliation Change In State Enacted Tax Ratepercent EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatepercent	-0.01	pure
CY2016	ck0001680048	Effective Income Tax Rate Reconciliation Change In State Enacted Tax Ratepercent EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatepercent	0.01	pure
CY2015Q3	ck0001680048	Class Of Warrants Or Rights Issued Warrants Term ClassOfWarrantsOrRightsIssuedWarrantsTerm	P10Y
CY2017	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	5700000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	140000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12948000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4129000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1571000	USD
CY2015Q1	us-gaap	Shares Outstanding SharesOutstanding		shares
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49976000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31628000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3571000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29052000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000000	USD
CY2016	ck0001680048	Class Of Warrant Or Right Warrants Issued ClassOfWarrantOrRightWarrantsIssued	138462	shares
CY2017	ck0001680048	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rightsdescription ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsdescription	If the Company has an initial public offering and raises sufficient equity capital so that it has cash equal to five times the amount of the portion of the proceeds of the NSC Note transferred to it, then NSC will receive a warrant to purchase the Companys stock equal to 25% of the outstanding note divided by the lowest price the Company sells its equity in its first third party financing
CY2017Q4	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	600000	USD
CY2017Q4	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3600000	USD
CY2017Q4	us-gaap	Land Improvements LandImprovements	3500000	USD
CY2017Q4	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	27043	acre
CY2017Q4	us-gaap	Security Deposit SecurityDeposit	800000	USD
CY2017Q4	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	1300000	USD
CY2017	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	2000000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The remaining 50% (the Performance Options) vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Company product candidate, (ii) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Company product candidate, (iii) 25% of the Performance Options vest upon the Companys achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the Performance Options vest upon the Companys achievement of a fully-diluted market capitalization of $1,000,000,000.
CY2017	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired	9600000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1700000	USD
CY2016	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	1400000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	413000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6424000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3848000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity		USD
	ck0001680048	Stock Issued During Period Value Class B Common Shares New Issues StockIssuedDuringPeriodValueClassBCommonSharesNewIssues	0	USD
	ck0001680048	Stock Issued During Period Value Issued To Parent New Issues StockIssuedDuringPeriodValueIssuedToParentNewIssues	0	USD
CY2017Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	40000000	USD
	ck0001680048	Stock Issuance Common Stock Issuable During Period StockIssuanceCommonStockIssuableDuringPeriod	190000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4466000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-4129000	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	147000	USD
CY2017	ck0001680048	Certificates Of Deposits250000 Or Less Description CertificatesOfDeposits250000OrLessDescription	the Company had approximately $40.0 million in certificates of deposit with no more than $250,000 at any individual institution.
CY2017	us-gaap	Common Stock Voting Rights CommonStockVotingRights	1.1
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2012000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7236000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3310000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	697000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	301000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	50000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	76000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	22000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	0	USD
CY2017Q4	ck0001680048	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	8000	USD
CY2016Q4	ck0001680048	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	13000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	178000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	89000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14615000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7637000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14615000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7637000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016	us-gaap	Professional Fees ProfessionalFees	120000	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	ck0001680048	Decreased In Deferred Tax Assets DecreasedInDeferredTaxAssets	5700000	USD
CY2017	ck0001680048	Payments For Security Depsots PaymentsForSecurityDepsots	251000	USD
CY2016	ck0001680048	Payments For Security Depsots PaymentsForSecurityDepsots	0	USD
	ck0001680048	Payments For Security Depsots PaymentsForSecurityDepsots	0	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	264000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	448000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	462000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	476000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1947000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3635000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	38000	USD
CY2017Q4	ck0001680048	Property Plant And Equipment Design Costs Capitalized PropertyPlantAndEquipmentDesignCostsCapitalized	1200000	USD
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05	pure
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.02	pure
	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.01	pure
	ck0001680048	Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Ratepercent EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatepercent	0	pure
	ck0001680048	Effective Income Tax Rate Reconciliation Change In State Enacted Tax Ratepercent EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatepercent	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.39	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2337000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2017	ck0001680048	Annual Fees Expenses On Founders Agreement AnnualFeesExpensesOnFoundersAgreement	500000	USD
CY2016	ck0001680048	Annual Fees Expenses On Founders Agreement AnnualFeesExpensesOnFoundersAgreement	500000	USD
	ck0001680048	Annual Fees Expenses On Founders Agreement AnnualFeesExpensesOnFoundersAgreement	400000	USD
CY2017	us-gaap	Professional Fees ProfessionalFees	120000	USD
CY2017	ck0001680048	Research Amd Development Licenses Expenditure Incurred But Not Yet Paid ResearchAmdDevelopmentLicensesExpenditureIncurredButNotYetPaid	500000	USD
CY2016	ck0001680048	Research Amd Development Licenses Expenditure Incurred But Not Yet Paid ResearchAmdDevelopmentLicensesExpenditureIncurredButNotYetPaid	0	USD
	ck0001680048	Research Amd Development Licenses Expenditure Incurred But Not Yet Paid ResearchAmdDevelopmentLicensesExpenditureIncurredButNotYetPaid	0	USD
CY2016Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10000000	USD
CY2017Q4	ck0001680048	Research And Development Expense Sponsored Research Payment ResearchAndDevelopmentExpenseSponsoredResearchPayment	800000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	USD

Files In Submission

Name	View Source	Status
0001144204-18-017988-index-headers.html	Edgar Link	pending
0001144204-18-017988-index.html	Edgar Link	pending
0001144204-18-017988.txt	Edgar Link	pending
0001144204-18-017988-xbrl.zip	Edgar Link	pending
ck0001680048-20171231.xml	Edgar Link	completed
ck0001680048-20171231.xsd	Edgar Link	pending
ck0001680048-20171231_cal.xml	Edgar Link	unprocessable
ck0001680048-20171231_def.xml	Edgar Link	unprocessable
ck0001680048-20171231_lab.xml	Edgar Link	unprocessable
ck0001680048-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv486570_10k.htm	Edgar Link	pending
tv486570_ex23-1.htm	Edgar Link	pending
tv486570_ex23-2.htm	Edgar Link	pending
tv486570_ex31-1.htm	Edgar Link	pending
tv486570_ex31-2.htm	Edgar Link	pending
tv486570_ex32-1.htm	Edgar Link	pending
tv486570_ex32-2.htm	Edgar Link	pending
tv486570_img01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBIO
MUSTANG BIO, INC. Stock $mbio

2017 Form 10-K Financial Statement

#000114420418017988 Filed on March 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO MUSTANG BIO, INC. Stock $mbio

2017 Form 10-K Financial Statement

#000114420418017988 Filed on March 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO
MUSTANG BIO, INC. Stock $mbio